These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31631357)

  • 1. Evaluating futility of a binary clinical endpoint using early read-outs.
    Van Lancker K; Vandebosch A; Vansteelandt S; De Ridder F
    Stat Med; 2019 Dec; 38(28):5361-5375. PubMed ID: 31631357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
    Lesaffre E; Edelman MJ; Hanna NH; Park K; Thatcher N; Willemsen S; Gaschler-Markefski B; Kaiser R; Manegold C
    Ann Oncol; 2017 Jul; 28(7):1419-1426. PubMed ID: 28184431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Futility Interim Design: A Predictive Probability of Success Approach with Time-to-Event Endpoint.
    Tang Z
    J Biopharm Stat; 2015; 25(6):1312-9. PubMed ID: 25379701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
    Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
    Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A group sequential Holm procedure with multiple primary endpoints.
    Ye Y; Li A; Liu L; Yao B
    Stat Med; 2013 Mar; 32(7):1112-24. PubMed ID: 23239078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
    Rufibach K; Heinzmann D; Monnet A
    Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints.
    Zocholl D; Kunz CU; Rauch G
    Stat Methods Med Res; 2023 Sep; 32(9):1749-1765. PubMed ID: 37489267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim analysis incorporating short- and long-term binary endpoints.
    Niewczas J; Kunz CU; König F
    Biom J; 2019 May; 61(3):665-687. PubMed ID: 30694566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints.
    Kunz CU; Friede T; Parsons N; Todd S; Stallard N
    J Biopharm Stat; 2015; 25(1):170-89. PubMed ID: 24697322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.
    Rufibach K; Jordan P; Abt M
    J Biopharm Stat; 2016; 26(2):191-201. PubMed ID: 25372950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.
    Stallard N; Kunz CU; Todd S; Parsons N; Friede T
    Stat Med; 2015 Oct; 34(23):3104-15. PubMed ID: 26112909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
    Stallard N
    Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.